Sartorius Stedim Biotech is currently covered by seven sell-side analysts. The following list shows their latest recommendation for the Sartorius Stedim Biotech share.
|Société Générale||Delphine Le Louët||22.07.2019||147.00||Hold|
|Oddo BHF||Christophe-Raphael Ganet||19.07.2019||115.00||Hold|
|New Street Research||Naresh Chouhan||19.07.2019||120.00||Buy|
|Gilbert Dupont||Guillaume Cuvillier||16.07.2019||119.00||Sell|
Based on an internal database, we have assigned the recommendations indicated below to buy, hold and sell categories. This list does not claim to be exhaustive.
Buy Buy | Outperform | Overweight
Hold Hold | Neutral
Sell Sell | Underperform | Underweight
The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.
Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.